Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Comparison of Two Formulations of 611 in Healthy Adults
NCT07042113Phase 1Not yet recruiting
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Jul 2025
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of SSGJ-611 in atopic dermatitis (AD) (2 arms), sponsored by 3S Guojian Pharmaceutical. Primary endpoints: Maximum Observed Serum Concentration at 57 days and Area Under the Concentration-Time Curve at 57 days. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
SSGJ-611
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07042113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07042113.